Cytokinetics Inc (CYTK) Stock Analysis

Cytokinetics Inc (CYTK) is a publicly traded company in the HEALTHCARE sector. It trades at $73.68, carries a market capitalization of $10.00B. This page summarizes the public market data, fundamentals, and frequently asked questions for CYTK, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Cytokinetics Inc currently has a Neutral sentiment score of 0.12.

About Cytokinetics Inc

Cytokinetics, Incorporated is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing innovative muscle activators and inhibitors for the treatment of debilitating diseases, including heart failure and various muscle disorders. With a strong and expanding pipeline, the company is advancing therapies that leverage its unique expertise in muscle biology, positioning Cytokinetics as a leader in therapeutic advancements in this ...

GNG Research Analysis

GNG Research scores Cytokinetics Inc (CYTK) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CYTK.

Frequently Asked Questions

Does CYTK pay dividends?

Cytokinetics Inc (CYTK) does not currently pay a regular dividend.

What is CYTK's market cap?

Cytokinetics Inc (CYTK) has a market capitalization of $10.00B with a current stock price of $73.68.